Bausch Health Americas, Inc is evaluating Amiselimod (MT-1303) in Ulcerative Colitis
The condition is Ulcerative Colitis.
A new clinical trial is recruiting patients in the following locations: United States.
The trial officially began in April 2021 and is planned to complete on October 2023.
The study will assess the efficacy and safety of oral MT-1303 compared to placebo at 12 weeks as the induction treatment in subjects with active mild to moderate ulcerative colitis (UC), as well as maintenance treatment with open-label MT-1303 for up to 36 weeks.
The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04857112
